KM Biologics plays a key role in safeguarding the health of Japan’s population, developing cutting-edge vaccines and blood-plasma products, and screening newborn babies.
The companies are combining their strengths to accelerate the commercialization of treatments and regenerative medicine for diseases with unmet needs by opening a new platform in Kashiwanoha Smart City.
